Credit Suisse AG Sells 20,397 Shares of Axovant Sciences Ltd (AXON)

Credit Suisse AG lessened its holdings in Axovant Sciences Ltd (NYSE:AXON) by 56.4% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 15,739 shares of the biotechnology company’s stock after selling 20,397 shares during the period. Credit Suisse AG’s holdings in Axovant Sciences were worth $235,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Primecap Management Co. CA increased its position in Axovant Sciences by 300.1% during the first quarter. Primecap Management Co. CA now owns 2,878,930 shares of the biotechnology company’s stock valued at $43,011,000 after acquiring an additional 2,159,428 shares during the last quarter. JPMorgan Chase & Co. increased its position in Axovant Sciences by 4.1% during the first quarter. JPMorgan Chase & Co. now owns 489,024 shares of the biotechnology company’s stock valued at $7,306,000 after acquiring an additional 19,129 shares during the last quarter. Nationwide Fund Advisors increased its position in Axovant Sciences by 70.9% during the first quarter. Nationwide Fund Advisors now owns 83,543 shares of the biotechnology company’s stock valued at $1,248,000 after acquiring an additional 34,654 shares during the last quarter. Teachers Advisors LLC increased its position in Axovant Sciences by 5.2% during the fourth quarter. Teachers Advisors LLC now owns 41,303 shares of the biotechnology company’s stock valued at $513,000 after acquiring an additional 2,038 shares during the last quarter. Finally, Wells Fargo & Company MN increased its position in Axovant Sciences by 34.3% during the first quarter. Wells Fargo & Company MN now owns 22,435 shares of the biotechnology company’s stock valued at $335,000 after acquiring an additional 5,733 shares during the last quarter.

Axovant Sciences Ltd (NYSE AXON) opened at 24.99 on Friday. Axovant Sciences Ltd has a 12 month low of $11.01 and a 12 month high of $27.98. The company has a 50 day moving average of $21.33 and a 200 day moving average of $21.33. The stock’s market capitalization is $2.69 billion.

Axovant Sciences (NYSE:AXON) last released its earnings results on Monday, August 7th. The biotechnology company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.12). On average, equities analysts predict that Axovant Sciences Ltd will post ($2.33) EPS for the current year.

AXON has been the topic of a number of research analyst reports. Jefferies Group LLC set a $40.00 price target on shares of Axovant Sciences and gave the stock a “buy” rating in a report on Friday, August 25th. Evercore ISI initiated coverage on shares of Axovant Sciences in a report on Friday, September 8th. They issued an “outperform” rating and a $30.00 price target on the stock. CIBC upped their price target on shares of Axovant Sciences from $26.00 to $30.00 and gave the stock an “outperform” rating in a report on Wednesday, June 14th. Oppenheimer Holdings, Inc. upped their price target on shares of Axovant Sciences from $26.00 to $30.00 and gave the stock an “outperform” rating in a report on Wednesday, June 14th. Finally, BidaskClub upgraded shares of Axovant Sciences from a “hold” rating to a “buy” rating in a report on Friday, June 23rd. Four analysts have rated the stock with a sell rating and nine have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $26.05.

TRADEMARK VIOLATION WARNING: “Credit Suisse AG Sells 20,397 Shares of Axovant Sciences Ltd (AXON)” was posted by BBNS and is the sole property of of BBNS. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this piece of content can be accessed at https://baseballnewssource.com/markets/axovant-sciences-ltd-axon-shares-sold-by-credit-suisse-ag/1604058.html.

Axovant Sciences Profile

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Institutional Ownership by Quarter for Axovant Sciences (NYSE:AXON)

Receive News & Ratings for Axovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd and related companies with our FREE daily email newsletter.

 


Latest News

Los Angeles Dodgers Waiting But Magic Number Down to One
Los Angeles Dodgers Waiting But Magic Number Down to One
Young Girl Hit by Foul Ball Rushed to Hospital
Young Girl Hit by Foul Ball Rushed to Hospital
New Home Run Record Reached in Major League Baseball
New Home Run Record Reached in Major League Baseball
Will 2017 MLB Season End with No 20-Game Winner?
Will 2017 MLB Season End with No 20-Game Winner?
Cleveland Indians Winning Streak Snapped at 22
Cleveland Indians Winning Streak Snapped at 22
Tigers Player Might Play All Nine Positions During Same Game
Tigers Player Might Play All Nine Positions During Same Game


Leave a Reply

 
© 2006-2017 BBNS.